Yarrow Bioscience, Inc. (VYNE) Form 8-K — Jul 28, 2026
$VYNEForm 8-KItems 1.01, 2.01, 2.02, 3.02, 3.03, 5.01, 5.02, 5.03, 5.05, 7.01, 9.01Filed Jul 28, 2026, 5:11 PM ET0001104659-26-087601Original filing
VYNE Therapeutics Inc. completed its merger with Yarrow Bioscience Inc., changing its name to Yarrow Bioscience Inc. and effective immediately placing Pre-Merger Yarrow stockholders in control of approximately 97% of the combined company. The merger assigned VYNE a valuation of $8.5 million and Yarrow a valuation of $272.9 million, establishing an exchange ratio of 0.7171 shares of VYNE common stock for each share of Yarrow common stock.
Key figures
- Exchange Ratio
- 0.7171
- Vyne Valuation
- 8500000
- Dividend Amount
- 17300000
- Yarrow Valuation
- 272900000
- Dividend Per Share
- 0.40242
- Ownership Vyne Pct
- 3%
- Series AFinancing
- 100000000
- Reverse Split Ratio
- 1-for-50
- Shares Outstanding
- 28,584,308
- Ownership Yarrow Pct
- 97%
- Pre Closing Financing
- 100000000
- Ceo Base Salary
- 660000
- Coo Base Salary
- 470000
Price after filing
1 day: +8.6%7 days: +35.3%30 days: +41.3%
Close on the filing date to close N calendar days later (from $28.05). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.